Evidence map›Paper›PMID 34023527›Full record

ArticleOsteoarthritis and cartilage2022

The burden of OA-health services and economics.

V P Leifer, J N Katz, E Losina

2 registry-linked trialsAbstract read
In one paragraph

Article in Osteoarthritis and cartilage, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 273 papers, 9 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
273citing papers in PubMed, 9 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06351059 unknown statusnot on this mapstarted 2023, after this paper: background citation

Acoustic Emission Biomarkers for the Detection and Monitoring of Early Knee Osteoarthritis

TypeobservationalSponsorSchulthess KlinikRan2023 to 2024Enrolled120ConditionsOsteoarthritis, Knee, DiagnosisArmsInModi acoustic emission analysis
NCT07491367 phase4recruitingnot on this mapstarted 2026, after this paper: background citation

Pilot Exploration of Platelet Characterization of Platelet Rich Plasma Created by Two Different Systems

TypeinterventionalSponsorUniversity of California, San FranciscoRan2026 to 2028Enrolled20ConditionsKnee Osteoarthristis, Cartilage Damage, Platelet Rich Plasma, Platelet Rich Plasma InjectionArmsPlatelet Rich Plasma, Emcyte PurePRP Supraphysiologic Concentrating System, APEX Biologix XCELL PRP System
3 · Its place in the literature

Who cites it

273 citing papers in PubMed, 9 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article

213 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

V P LeiferOrthopaedic and Arthritis Center for Outcomes Research (OrACORe), Policy and Innovation Evaluation in Orthopaedic Treatments (PIVOT) Center, Department of Orthopaedic Surgery, Brigham and Women's Hospital, Boston, MA, USA. Electronic address: vleifer@bwh.harvard.edu.
J N KatzOrthopaedic and Arthritis Center for Outcomes Research (OrACORe), Policy and Innovation Evaluation in Orthopaedic Treatments (PIVOT) Center, Department of Orthopaedic Surgery, Brigham and Women's Hospital, Boston, MA, USA; Harvard Medical School, Boston, MA, USA; Section of Clinical Sciences, Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, USA; Departments of Epidemiology and Environmental Health, Harvard T.H. Chan School of Public Health, Boston, MA, USA. Electronic address: jnkatz@bwh.harvard.edu.
E LosinaOrthopaedic and Arthritis Center for Outcomes Research (OrACORe), Policy and Innovation Evaluation in Orthopaedic Treatments (PIVOT) Center, Department of Orthopaedic Surgery, Brigham and Women's Hospital, Boston, MA, USA; Harvard Medical School, Boston, MA, USA; Section of Clinical Sciences, Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, USA; Department of Biostatistics, Boston University School of Public Health, Boston, MA, USA. Electronic address: elosina@bwh.harvard.edu.

Funding

VERITY: Value and Evidence in Rheumatology using bioInformaTics, and advanced analYticsP30AR072577 · NIAMS · BRIGHAM AND WOMEN'S HOSPITAL · PI Daniel Hal Solomon · 2017 to 2026
$9.8M
Research and Evaluation Support Core Unit (RESCU Core)P30AR072571 · NIAMS · BOSTON UNIVERSITY MEDICAL CAMPUS · PI TUHINA NEOGI · 2019 to 2026
$6.9M
Optimizing the value of pain management in knee OA patients with comorbiditiesR01AR074290 · NIAMS · BRIGHAM AND WOMEN'S HOSPITAL · PI Elena Losina · 2018 to 2026
$5.9M
Patient Oriented Research and Mentoring Program in OrthopedicsK24AR057827 · NIAMS · BRIGHAM AND WOMEN'S HOSPITAL · PI LOSINA, ELENA · 2010 to 2019
$1.7M
The Role of Urate in Knee Osteoarthritis-Related Inflammation, Pathology and PainK24AR070892 · NIAMS · BOSTON UNIVERSITY MEDICAL CAMPUS · PI TUHINA NEOGI · 2017 to 2026
$1.1M
NIAMS NIH HHS K24 AR057827NIAMS NIH HHS K24 AR070892NIAMS NIH HHS P30 AR072571NIAMS NIH HHS P30 AR072577NIAMS NIH HHS R01 AR074290
6 · The paper itself

Abstract

Osteoarthritis (OA) is a highly prevalent and disabling condition that affects over 7% of people globally (528 million people). Prevalence levels are even higher in countries with established market economies, which have older demographic profiles and a higher prevalence of obesity, such as the US (14%). As the 15th highest cause of years lived with disability (YLDs) worldwide, the burden OA poses to individuals is substantial, characterized by pain, activity limitations, and reduced quality of life. The economic impact of OA, which includes direct and indirect (time) costs, is also substantial, ranging from 1 to 2.5% of gross national product (GNP) in countries with established market economies. In regions around the world, the average annual cost of OA for an individual is estimated between $700-$15,600 (2019 USD). Though trends in OA prevalence vary by geography, the prevalence of OA is projected to rise in regions with established market economies such as North America and Europe, where populations are aging and the prevalence of obesity is rising.

Indexed as

Cost of IllnessHealth ServicesHumansOsteoarthritisPrevalenceDirect medical costs of osteoarthritisEpidemiology of osteoarthritisHealth servicesIndirect medical costs of osteoarthritisIndividual and societal burdens of osteoarthritisOsteoarthritis

Identifiers

PMID34023527
PMCPMC8605034

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.